Otsuka Pharmaceutical Co., Ltd.

April 26, 2022

Otsuka and Ai-BrainScience Announce Sales Collaboration Agreement
for New Cognitive Function Testing Application That Uses Eye Tracking Technology

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ai-BrainScience Inc. (Ai-BrainScience) announce that we have signed an exclusive sales collaboration agreement in Japan for a cognitive function testing application that uses eye movement (development code : AiBS-01). This product has the potential to become the first dementia diagnosis application to receive regulatory approval in Japan.

Eye tracking technology developed by Ai-BrainScience uses the AiBS-01 cognitive function testing application installed on an iPad or other tablet. It is a new method to determine cognitive function in a non-invasive, simple, objective, and quantitative manner using dataobtained from the biological behavior of eye movements to images and videos. By looking at the screen according to the contents displayed on the monitor screen, cognitive functions are evaluated according to the MMSE (Mini-Mental State Examination) assessment items. This makes it possible to perform a cognitive function evaluation easily and stress-free in approximately three minutes.

Clinical trial in Japan has already been completed, and Ai-BrainScience filed an application for manufacturing and marketing approval of this application with the Ministry of Health, Labour and Welfare in December 2021. Under the terms of the agreement, Otsuka Pharmaceutical will exclusively market AiBS-01 in Japan and pay Ai-BrainScience an upfront payment, regulatory and sales milestone payments, and royalties based on net sales.